On 20 May 2022 the President of the Agency for Health Technology Assessment and Tariff System issued the following recommendation:
Recommendation No. 43/2022 of 20 May 2022 of the President of the Agency for Health Technology Assessment and Tariff System on the inclusion in the reimbursement procedure of the medicinal product: Tysabri, natalizumab, concentrate for solution for infusion, 20 mg/ml, 1, vial. 15 ml, GTIN 05909990084333, for the indication under the new drug programme “Treatment of multiple sclerosis (ICD-10 G35) with natalizumab administered intravenously”.